SL
Labidi-Galy, Sana Intidhar
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer | JCO precision oncology |  | 2025 | 11 | 26 | ||
| Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix | Gynecologic oncology reports | | 2024 | 99 | 72 | ||
| Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting : final analysis of LUCY | Breast cancer research and treatment | | 2024 | 96 | 429 | ||
| Identification of clinically relevant t cell receptors for personalized t cell therapy using combinatorial algorithms | Nature biotechnology | | 2024 | 161 | 45 | ||
| Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors | Gynecologic oncology reports | | 2024 | 15 | 16 | ||
| Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapy | Journal of pharmaceutical and biomedical analysis | | 2024 | 25 | 15 | ||
| Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma | Nature communications | | 2024 | 66 | 33 | ||
| H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours | Nature communications | | 2024 | 130 | 59 | ||
| Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon : a retrospective study | Swiss medical weekly | | 2023 | 61 | 51 | ||
| Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity | BMJ open | | 2023 | 495 | 89 | ||
| Changes of health-related quality of life 6 months after high-risk oncological upper gastrointestinal and hepatobiliary surgery: a single-centre prospective observational study (ChangeQol Study) | BMJ open | | 2023 | 164 | 196 | ||
| Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics | International journal of cancer | | 2023 | 509 | 85 | ||
| The clinical challenges of homologous recombination proficiency in ovarian cancer : from intrinsic resistance to new treatment opportunities | Cancer drug resistance | | 2023 | 78 | 32 | ||
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | 2022 | 239 | 161 | ||
| Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels | Revue médicale suisse | | 2022 | 163 | 92 | ||
| Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer | Seminars in cancer biology | | 2021 | 50 | 33 | ||
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | | 2021 | 291 | 351 | ||
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? | Cancer treatment reviews | | 2021 | 72 | 110 | ||
| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes | Scientific Reports | | 2020 | 331 | 329 | ||
| Pathogenesis of ovarian cancer | | 2020 | 775 | 605 | |||
| Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation | Gynecologic Oncology Reports | | 2020 | 288 | 181 | ||
| Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets — a narrative review | Annals of translational medicine | | 2020 | 206 | 194 | ||
| BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients | Breast Cancer Research and Treatment |  | 2019 | 438 | 3 | ||
| Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors | The Journal of Pathology | | 2018 | 889 | 6 | ||
| High grade serous ovarian carcinomas originate in the fallopian tube | Nature Communications | | 2017 | 518 | 420 | ||
| Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer | Journal of Translational Medicine | | 2017 | 478 | 199 |
